FDA Approves Innoviva's Bacterial Pneumonia Treatment
By Sabela Ojea
The Food and Drug Administration said Tuesday that it approved Innoviva's Xacduro pneumonia treatment, which fights the Acinetobacter bacteria.
The federal regulator said Xacduro, which treats ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia, is hard to treat and poses a great threat to human health.
The FDA granted approval of Xacduro, administered by intravenous infusion, to Entasis Therapeutics, acquired by the pharma company Innoviva last year.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
May 23, 2023 18:55 ET (22:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact